Cargando…
Neurodegeneration and Neuroprotection in Glaucoma
Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
YJBM
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797839/ https://www.ncbi.nlm.nih.gov/pubmed/27505018 |
_version_ | 1782422035916390400 |
---|---|
author | Gauthier, Angela C. Liu, Ji |
author_facet | Gauthier, Angela C. Liu, Ji |
author_sort | Gauthier, Angela C. |
collection | PubMed |
description | Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease even shares some characteristics with other central nervous system degenerative disorders. Glaucoma destroys neurons through oxidative stress, impairment in axonal transport, neuroinflammation, and excitotoxicity. Autophagy may promote or inhibit disease progression. Currently, lowering intraocular pressure is the only way proven to delay glaucoma advancement. However, many new therapies are being developed, including antioxidants, adenosine receptor antagonists, Rho-pathway inhibitors, stem cell therapy, and neurotrophic factors. These therapies focus on neuroprotection, and they may eventually halt glaucoma progression or reverse the process of the disease itself. |
format | Online Article Text |
id | pubmed-4797839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | YJBM |
record_format | MEDLINE/PubMed |
spelling | pubmed-47978392016-03-30 Neurodegeneration and Neuroprotection in Glaucoma Gauthier, Angela C. Liu, Ji Yale J Biol Med Review Glaucoma is the principal cause of irreversible blindness in the world. The disease leads to progressive optic nerve degeneration with a gradual loss of retinal ganglion cells. Neurodegeneration in glaucoma extends beyond the eye into the lateral geniculate nucleus and visual cortex, and the disease even shares some characteristics with other central nervous system degenerative disorders. Glaucoma destroys neurons through oxidative stress, impairment in axonal transport, neuroinflammation, and excitotoxicity. Autophagy may promote or inhibit disease progression. Currently, lowering intraocular pressure is the only way proven to delay glaucoma advancement. However, many new therapies are being developed, including antioxidants, adenosine receptor antagonists, Rho-pathway inhibitors, stem cell therapy, and neurotrophic factors. These therapies focus on neuroprotection, and they may eventually halt glaucoma progression or reverse the process of the disease itself. YJBM 2016-03-24 /pmc/articles/PMC4797839/ /pubmed/27505018 Text en Copyright ©2016, Yale Journal of Biology and Medicine https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons CC BY-NC license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use the material for commercial purposes. |
spellingShingle | Review Gauthier, Angela C. Liu, Ji Neurodegeneration and Neuroprotection in Glaucoma |
title | Neurodegeneration and Neuroprotection in Glaucoma |
title_full | Neurodegeneration and Neuroprotection in Glaucoma |
title_fullStr | Neurodegeneration and Neuroprotection in Glaucoma |
title_full_unstemmed | Neurodegeneration and Neuroprotection in Glaucoma |
title_short | Neurodegeneration and Neuroprotection in Glaucoma |
title_sort | neurodegeneration and neuroprotection in glaucoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797839/ https://www.ncbi.nlm.nih.gov/pubmed/27505018 |
work_keys_str_mv | AT gauthierangelac neurodegenerationandneuroprotectioninglaucoma AT liuji neurodegenerationandneuroprotectioninglaucoma |